[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1037918A1 - olymorph of ritonavir. - Google Patents

olymorph of ritonavir.

Info

Publication number
HK1037918A1
HK1037918A1 HK01107867A HK01107867A HK1037918A1 HK 1037918 A1 HK1037918 A1 HK 1037918A1 HK 01107867 A HK01107867 A HK 01107867A HK 01107867 A HK01107867 A HK 01107867A HK 1037918 A1 HK1037918 A1 HK 1037918A1
Authority
HK
Hong Kong
Prior art keywords
olymorph
ritonavir
Prior art date
Application number
HK01107867A
Other languages
English (en)
Inventor
John F Bauer
Azita Saleki-Gerhardt
Bikshandarkoil A Narayanan
Sanjay R Chemburkar
Ketan Patel
Harry O Spiwek
Philip E Bauer
Kimberly A Allen
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26817251&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1037918(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of HK1037918A1 publication Critical patent/HK1037918A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28Radicals substituted by nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicinal Preparation (AREA)
HK01107867A 1998-07-20 2001-11-08 olymorph of ritonavir. HK1037918A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11934598A 1998-07-20 1998-07-20
US32609399A 1999-06-04 1999-06-04
PCT/US1999/016334 WO2000004016A2 (en) 1998-07-20 1999-07-19 Polymorph of ritonavir

Publications (1)

Publication Number Publication Date
HK1037918A1 true HK1037918A1 (en) 2002-02-22

Family

ID=26817251

Family Applications (2)

Application Number Title Priority Date Filing Date
HK01107867A HK1037918A1 (en) 1998-07-20 2001-11-08 olymorph of ritonavir.
HK09100857A HK1121155A1 (en) 1998-07-20 2009-01-29 A pharmaceutical composition comprising form ii crystalline ritonavir and a preparation thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK09100857A HK1121155A1 (en) 1998-07-20 2009-01-29 A pharmaceutical composition comprising form ii crystalline ritonavir and a preparation thereof

Country Status (30)

Country Link
EP (4) EP2298751A3 (el)
JP (4) JP4815050B2 (el)
KR (3) KR100853371B1 (el)
CN (5) CN102153524A (el)
AR (5) AR019431A1 (el)
AT (3) ATE261947T1 (el)
AU (1) AU768207B2 (el)
BG (4) BG65150B1 (el)
BR (1) BR9912010A (el)
CA (3) CA2674800A1 (el)
CO (1) CO5090830A1 (el)
CY (2) CY1111600T1 (el)
CZ (2) CZ307116B6 (el)
DE (2) DE69915628T2 (el)
DK (3) DK2017269T3 (el)
ES (3) ES2372990T3 (el)
HK (2) HK1037918A1 (el)
HU (3) HU230150B1 (el)
ID (1) ID27996A (el)
IL (4) IL140492A0 (el)
MY (2) MY121765A (el)
NO (2) NO318385B1 (el)
NZ (2) NZ509125A (el)
PL (2) PL194710B1 (el)
PT (3) PT2017269E (el)
SI (3) SI2017269T1 (el)
SK (3) SK286388B6 (el)
TR (1) TR200100171T2 (el)
TW (3) TWI227713B (el)
WO (1) WO2000004016A2 (el)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894171B1 (en) 1998-07-20 2005-05-17 Abbott Laboratories Polymorph of a pharmaceutical
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
ATE429224T1 (de) * 1999-06-04 2009-05-15 Abbott Lab Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor
MXPA03010771A (es) * 2001-05-25 2004-07-01 Abbott Lab Capsulas elasticas blandas que comprenden ritonavir y/o lopinavir.
TWI286476B (en) * 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
US7205413B2 (en) 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
US20080312300A1 (en) * 2005-05-30 2008-12-18 Yoginder Pal Sachdeva Processes for the Preparation of Stable Polymorphic Form I of Ritonavir
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
CN102898398B (zh) * 2011-07-27 2015-01-14 上海迪赛诺药业有限公司 一种制备i型利托那韦多晶型结晶的方法
WO2013131646A1 (en) 2012-03-07 2013-09-12 Ratiopharm Gmbh Dosage form comprising lopinavir and ritonavir
HUE027829T2 (en) 2012-03-07 2016-11-28 Ratiopharm Gmbh Dosage forms containing non-crystalline lopinavir and crystalline ritonavir
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
EP3129009A1 (en) 2014-04-08 2017-02-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN106749085B (zh) * 2016-12-23 2019-05-24 东北制药集团股份有限公司 一种制备利托那韦的方法
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
RU2759544C1 (ru) * 2021-01-29 2021-11-15 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
EP0674513B1 (en) * 1992-12-29 1996-09-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US5567823A (en) * 1995-06-06 1996-10-22 Abbott Laboratories Process for the preparation of an HIV protease inhibiting compound
US6037157A (en) * 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6160122A (en) 1996-06-28 2000-12-12 Abbott Laboratories Process for the preparation of a disubstituted thiazole
ZA9710071B (en) 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
MY121765A (en) * 1998-07-20 2006-02-28 Abbott Lab Polymorph of ritonavir
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
ATE429224T1 (de) * 1999-06-04 2009-05-15 Abbott Lab Arzneizubereitungen enthaltend mindestens einen hiv preoteaseinhibitor

Also Published As

Publication number Publication date
HUP0103823A3 (en) 2003-05-28
WO2000004016A3 (en) 2000-03-30
SI1097148T1 (en) 2004-10-31
EP1418174B1 (en) 2009-03-18
ATE261947T1 (de) 2004-04-15
SI1418174T1 (sl) 2009-08-31
NZ509125A (en) 2003-02-28
IL187181A (en) 2009-09-01
JP4815050B2 (ja) 2011-11-16
KR100853371B1 (ko) 2008-08-22
CZ307116B6 (cs) 2018-01-24
CY1111600T1 (el) 2015-10-07
NO327320B1 (no) 2009-06-08
SK287586B6 (sk) 2011-03-04
CA2674800A1 (en) 2000-01-27
JP2010270135A (ja) 2010-12-02
KR20060118022A (ko) 2006-11-17
JP5732212B2 (ja) 2015-06-10
AR059764A2 (es) 2008-04-30
BG66140B1 (bg) 2011-07-29
WO2000004016A2 (en) 2000-01-27
CA2337846A1 (en) 2000-01-27
EP2017269B1 (en) 2011-11-23
JP2017061475A (ja) 2017-03-30
SK287381B6 (sk) 2010-08-09
IL191582A0 (en) 2008-12-29
CN1310715A (zh) 2001-08-29
CN1502613A (zh) 2004-06-09
ES2214038T3 (es) 2004-09-01
HU0800267D0 (en) 2008-06-30
ES2372990T3 (es) 2012-01-30
CO5090830A1 (es) 2001-10-30
BG110080A (bg) 2008-11-28
CA2510949C (en) 2009-11-17
DE69915628T2 (de) 2004-08-12
EP1418174A3 (en) 2004-06-23
PT1418174E (pt) 2009-06-08
EP2298751A2 (en) 2011-03-23
DK1097148T3 (da) 2004-04-26
EP1418174A2 (en) 2004-05-12
JP2002520410A (ja) 2002-07-09
EP2017269A3 (en) 2009-06-10
CZ298188B6 (cs) 2007-07-18
TWI227713B (en) 2005-02-11
NO20010298D0 (no) 2001-01-18
ATE425974T1 (de) 2009-04-15
AU5003799A (en) 2000-02-07
KR100740796B1 (ko) 2007-07-20
CN102153524A (zh) 2011-08-17
TW200716550A (en) 2007-05-01
SK922001A3 (en) 2001-07-10
NO20010298L (no) 2001-01-18
IL191582A (en) 2016-02-29
BR9912010A (pt) 2001-04-10
EP2017269A2 (en) 2009-01-21
KR20010072003A (ko) 2001-07-31
CN101966180A (zh) 2011-02-09
JP2014074047A (ja) 2014-04-24
BG109682A (bg) 2007-03-30
DE69940616D1 (de) 2009-04-30
EP2298751A3 (en) 2011-08-17
SI2017269T1 (sl) 2012-02-29
ID27996A (id) 2001-05-03
HU0800266D0 (en) 2008-06-30
HK1121155A1 (en) 2009-04-17
NO318385B1 (no) 2005-03-14
AR059763A2 (es) 2008-04-30
TR200100171T2 (tr) 2001-05-21
MY121765A (en) 2006-02-28
EP2017269A8 (en) 2009-09-30
CY1112139T1 (el) 2015-11-04
TWI271400B (en) 2007-01-21
DK1418174T3 (da) 2009-05-18
NZ522690A (en) 2004-04-30
PT1097148E (pt) 2004-05-31
CN101259128A (zh) 2008-09-10
KR20040081137A (ko) 2004-09-20
NO20042393L (no) 2001-01-18
AR019431A1 (es) 2002-02-20
PL194710B1 (pl) 2007-06-29
CN1310715B (zh) 2010-11-03
MY145265A (en) 2012-01-13
PL348033A1 (en) 2002-05-06
ATE534636T1 (de) 2011-12-15
CZ2006533A3 (cs) 2001-05-16
HU227540B1 (en) 2011-08-29
HUP0103823A2 (hu) 2002-02-28
AR049658A2 (es) 2006-08-23
EP2017269A9 (en) 2009-10-14
EP1097148A2 (en) 2001-05-09
AU768207B2 (en) 2003-12-04
BG65150B1 (bg) 2007-04-30
KR100793046B1 (ko) 2008-01-10
EP1097148B1 (en) 2004-03-17
DE69915628D1 (en) 2004-04-22
PT2017269E (pt) 2011-12-20
HU230150B1 (hu) 2015-09-28
AR044029A2 (es) 2005-08-24
BG105197A (en) 2001-10-31
ES2322759T3 (es) 2009-06-26
CA2337846C (en) 2006-02-21
IL140492A0 (en) 2002-02-10
IL140492A (en) 2010-12-30
DK2017269T3 (da) 2012-03-05
SK286388B6 (sk) 2008-09-05
IL187181A0 (en) 2008-02-09
PL213978B1 (pl) 2013-05-31
CA2510949A1 (en) 2000-01-27
BG65963B1 (bg) 2010-07-30
TWI362382B (en) 2012-04-21
CZ2001203A3 (en) 2001-05-16
HU229999B1 (en) 2015-04-28

Similar Documents

Publication Publication Date Title
GB2342193B (en) Addition circuitry
ZA996185B (en) Sulfanylsilanes.
ZA200005136B (en) Dihydropyrimides.
HK1042653A1 (en) External preparation.
ZA99254B (en) Benzosulfone derivatives.
ZA200101637B (en) Cyclone.
GB0030695D0 (en) Early case
ZA991272B (en) Novel thiobenzamides.
HK1037918A1 (en) olymorph of ritonavir.
ZA992443B (en) Hydroxy-methyl-hexanones.
ZA991550B (en) Cyclohexanediole derivatives.
DE59904407D1 (en) Chromanderivate
ZA995325B (en) Methylcyclotetradec-5-en-1-ones.
ZA993123B (en) Trisresorcinyltriazines.
ZA991575B (en) N-sulphonyl and N-sulphinyl phenylglycinamide.
HK1021879A1 (en) Carrying case.
DE59900471D1 (en) Inchbremseinrichtung
GB9814227D0 (en) The worthybag
HK1028588A1 (en) Case.
GB9801584D0 (en) The maitriser
EG23239A (en) Preparation of haemagel.
GB9804598D0 (en) The gobbler
ZA993690B (en) Dam-scraper.
CA84117S (en) Ring
CA83395S (en) Ring

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20190718